Tipelukast
Small molecule
Evidence outlook
Type 2 Diabetes: topline reported 2026-09-28
The sponsor reported topline results on 2026-09-28 (Phase 2 MN-001-NATG-202 topline: Week 24 triglyceride and liver-fat changes not statistically significant vs placebo). The announcement is listed under Regulatory events.
Also in development:MASH / NASH · Phase 2Hypertriglyceridemia · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
Registered studies that name Type 2 Diabetes were reviewed; none met the criteria for featured evidence.
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Hypertriglyceridemia: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tipelukast: this drug | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | Weak signal | NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results. | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Olezarsen (Tryngolza) | Phase 3 | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Reliable signal | NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083. | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). | |
| Pravafenix | Phase 3(overall) | Small molecule | HMG-CoA reductase / PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Saroglitazar (Lipaglyn) | Phase 3(overall) | Small molecule | PPAR-alpha/PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| MAR001 | Phase 2 | Monoclonal antibody | ANGPTL4 | Weak signal | Featured results are safety only in this race | |
| RBD5044 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| TLC-2716 | Phase 2 | Small molecule | Liver X receptor (LXR) | not yet graded | No reviewed efficacy summary in this indication | |
| JMT202 | Phase 1/2 | Monoclonal antibody | β-Klotho (KLB) | not yet graded | No reviewed efficacy summary in this indication | |
| RN0361 | Phase 1/2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-APOC3 | Phase 1(overall) | RNA / oligonucleotide | Apolipoprotein C-III (APOC3) | not yet graded | No reviewed efficacy summary in this indication | |
| ISH0688 | Phase 1 | Protein / enzyme therapeutic | FGF21 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Kylo-12 | Phase 1 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| VERVE-201 | Phase 1 | Gene therapy / editing | ANGPTL3 gene (hepatocyte genomic DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tipelukast to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent